BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced positive data from its EfficAPSI real-world study. Presented at the 2022 European Academy of Allergy and Clin
MISSISSAUGA, Ontario--(BUSINESS WIRE)--$MDX #SkinCancer--MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $4 million by issuance o
BURLINGTON, Ontario--(BUSINESS WIRE)--Rapid Dose Therapeutics Corp. (“RDT”), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, announces that, further to its press release dated June 16, 2022 (
- Phase II acute pain program to initiate in early calendar Q4 2022 - Ended year with $55 million in cash and equivalents, providing over two years of runway TORONTO--(BUSINESS WIRE)--$ATBPF--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical
NEW YORK--(BUSINESS WIRE)--Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) (“Columbia Care” or the “Company”), one of the largest and most experienced cultivators, manufacturers and providers of cannabis products in the U.S.,
Bebtelovimab continues to maintain neutralization activity against all known variants of interest and concern VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL #AbCellera--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial an
A2a/A2b antagonist candidate, M1069, jointly discovered by Domain Therapeutics and Merck entered into a first-in-human study to investigate the safety, tolerability, PK/PD and clinical activity in patients with metastatic or locally advanced unresectabl
- Presentation title: “Long-Term Persistence of Anti-HBs Antibodies after Vaccination with a 3-Antigen HBV Vaccine Compared with a Single-Antigen HBV Vaccine” CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceuti
Dr. Huang brings more than 30 years of biopharma experience, most recently as Chief Executive Officer and President of Flagship Pioneering start-up Cygnal Therapeutics Dunad appoints new CEO as company establishes U.S. operations, continues to expand
The Manitoba government has updated the Small Business Minimum Wage Adjustment Program online application to allow businesses to set customized pay periods when claiming eligible employee wage subsidies.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.